9.300USD+9.300After-hours 07/30, 20:00 (ET)
489.33MMarket Cap
LossP/E TTM
Key Figures
9.650Open
9.900High
1.09MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.14%Turnover Ratio
9.600Prev. Close
9.460Low
7.20MTurnover
LossP/E Static
4.76P/B
0.00%Div Yield TTM
-69.65%ROA
16.19052wk High
0.89Volume Ratio
-227.10MNet Profit
50.89MShares
-5.5953EPS TTM
1.05Beta
-196.43%ROE
5.45552wk Low
4.58%Amplitude
-73.22%Gross Margin
489.33MMarket Cap
-4.24Reward/Risk
4.69%Risk Rate
Currency: USD Updated: 2026-07-29 Key Insights
Regenxbio Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 93 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.00.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Regenxbio Inc Highlights
StrengthsRisks
Regenxbio Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
27
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regenxbio Inc Info
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Ticker SymbolRGNX
CompanyRegenxbio Inc
CEOSimpson (Curran M)
Websitehttps://regenxbio.com/
Shareholders
FAQs
What is the current price of Regenxbio Inc (RGNX)?
The current price of Regenxbio Inc (RGNX) is 9.62.
What is the symbol of Regenxbio Inc?
The ticker symbol of Regenxbio Inc is RGNX.
What is the 52-week high of Regenxbio Inc?
The 52-week high of Regenxbio Inc is 16.19.
What is the 52-week low of Regenxbio Inc?
The 52-week low of Regenxbio Inc is 5.46.
What is the market capitalization of Regenxbio Inc?
The market capitalization of Regenxbio Inc is 489.33M.
Is Regenxbio Inc (RGNX) currently rated as Buy, Hold, or Sell?
According to analysts, Regenxbio Inc (RGNX) has an overall rating of Buy, with a price target of 26.00.
What is the Earnings Per Share (EPS TTM) of Regenxbio Inc (RGNX)?
The Earnings Per Share (EPS TTM) of Regenxbio Inc (RGNX) is -3.76.
